Study guide

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities

Key Takeaways Explain This Topic AI

FDA 21 CFR 58.33 names the Study Director as the single point of study control for technical conduct, interpretation, documentation, and reporting.

OECD GLP allows a Principal Investigator to supervise a delegated multi-site phase, but overall Study Director responsibility cannot be delegated.

For any given study, 21 CFR 58.35 requires the Quality Assurance Unit to be entirely separate from personnel directing and conducting that study.

GLP documents reconstructable quality; it does not by itself prove that the scientific design, species, or dose selection was valid.

FDA Part 58 applies to nonclinical safety studies intended to support research or marketing permits; EPA uses 40 CFR 160 (FIFRA) and 40 CFR 792 (TSCA).

Last updated: September 2026

Why DABT tests GLP execution

Domain I of the Diplomate of the American Board of Toxicology (DABT) exam spends substantial weight on conducting studies, not only designing them. ExamFinch independent study material for this section covers Good Laboratory Practice (GLP) as the quality system that lets a reviewer reconstruct what was planned, what was done, and what was reported. The three texts you will see named on items are the U.S. Food and Drug Administration (FDA) rule 21 CFR Part 58 , the U.S. Environmental Protection Agency (EPA) rules 40 CFR Part 160 (studies under the Federal Insecticide, Fungicide, and Rodenticide Act, FIFRA) and 40 CFR Part 792 (studies under the Toxic Substances Control Act, TSCA), and the Organisation for Economic Co-operation and Development ( OECD ) Principles of GLP.

Those frameworks share a named Study Director , an independent quality function, controlled written instructions, contemporaneous raw data , and an archive. They do not share one statute, one vocabulary, or one product-law trigger. A DABT item that asks who is accountable when in-life dosing, bioanalysis, and histopathology sit at three contract sites is testing whether you can keep single-point study control while still using an OECD Principal Investigator (PI) for a delegated phase.

What GLP is — and what it is not

OECD describes GLP as a managerial quality system covering the organizational process and the conditions under which nonclinical health and environmental safety studies are planned, performed, monitored, recorded, reported, and archived. FDA 21 CFR 58.1 prescribes GLP for nonclinical laboratory studies that support, or are intended to support, applications for research or marketing permits for FDA-regulated articles: human and animal drugs, biological products, medical devices for human use, food and color additives, animal food additives, and electronic products.

GLP does not prove scientific validity of the design. A study can be fully GLP-compliant and still use the wrong species, omit a needed endpoint, or choose doses that never approach a tolerated high dose. Inspectors and quality auditors ask whether the approved protocol was followed, whether original observations can be reconstructed, and whether the signed report matches the data. Whether the design was an appropriate test of the hypothesis is a separate toxicology judgment, taught in Domain I.A (design) and I.C (interpretation).

FDA 21 CFR 58.3 also carves out basic exploratory studies done only to see whether a test article has potential utility, or only to determine physical or chemical characteristics. Studies that use human subjects are clinical (Good Clinical Practice), not GLP. Commercial manufacture of clinical supplies is Good Manufacturing Practice. Early investigative pharmacology, screening cytotoxicity, and many discovery range-finders can therefore be run non-GLP even when they use animals — unless a sponsor later tries to submit them as the pivotal safety evidence. Field trials in animals are outside the FDA Part 58 definition of a nonclinical laboratory study; pesticide field phases are commonly in scope under EPA FIFRA GLP.

When GLP is required versus investigative work

Use GLP when the study is intended as regulatory safety evidence a receiving authority will rely on:

FDA: pivotal nonclinical safety (repeat-dose toxicity, genotoxicity packages submitted as safety evidence, reproductive and developmental toxicity, carcinogenicity, and safety pharmacology when the study is offered as GLP safety data) supporting an Investigational New Drug (IND) application, New Drug Application (NDA), Biologics License Application (BLA), or device research/marketing permit.

EPA FIFRA (40 CFR 160): health and environmental studies submitted to support pesticide registration.

EPA TSCA (40 CFR 792): health, environmental, and chemical-fate studies submitted under TSCA.

OECD Mutual Acceptance of Data (MAD): a study conducted to the OECD Principles in a facility under a MAD-compliant monitoring program can be accepted by participating governments without duplicative testing.

Investigative non-GLP work remains legitimate: mechanism probes, vehicle scouting, and dose-range finding that will not stand alone as the safety database. Label that work honestly in the protocol and report. A recurring failure mode is running an investigative study loosely, then attempting to “GLP-wash” the report after an unexpected finding appears.

FDA, EPA, and OECD side by side

Framework Typical studies a toxicologist submits Distinctive operational point

FDA 21 CFR Part 58 Nonclinical safety for FDA research or marketing permits Study Director is the single point of study control (21 CFR 58.33). Current Part 58 text is thinner than OECD on multi-site PIs.

EPA 40 CFR Part 160 FIFRA pesticide health and environmental studies Same GLP skeleton as FDA, scoped to pesticide data EPA will rely on; field phases are often included.

EPA 40 CFR Part 792 TSCA chemical health, ecological, and fate studies Same skeleton, scoped to TSCA testing rather than drugs or devices.

OECD Principles of GLP Nonclinical health and environmental safety (laboratory, greenhouse, or field; not human subjects) Defines a Principal Investigator for delegated multi-site phases; overall Study Director responsibility cannot be delegated. OECD says study plan where FDA says protocol .

Do not treat the table as permission to ignore OECD language on a U.S. IND. Many modern packages are multi-site. Sponsors write OECD-style PI assignments into the protocol so each test site has a named scientific lead, while one Study Director still signs the assembled report.

Study Director duties (21 CFR 58.33)

For each nonclinical laboratory study, a scientist or other professional with appropriate education, training, and experience (or a combination) is identified as the Study Director . That person has overall responsibility for technical conduct, interpretation, analysis, documentation, and reporting, and represents the single point of study control . The Study Director must assure that:

The protocol, including any change, is approved as provided by 21 CFR 58.120 and is followed.

Experimental data, including unanticipated responses of the test system, are accurately recorded and verified.

Unforeseen circumstances that may affect quality and integrity are noted when they occur, and corrective action is taken and documented.

Test systems are as specified in the protocol.

Applicable GLP regulations are followed.

Raw data, documentation, protocols, specimens, and the final report are transferred to the archives during or at the close of the study.

If a gavage technician loads the mid-dose syringe into a high-dose cage at 09:10, the Study Director is the person who must know, document, and decide whether the study remains interpretable. Accountability does not dissolve into a team of equally responsible scientists.

Principal Investigator in multi-site studies

OECD GLP created the Principal Investigator because packages split geographically: 13-week in-life at a contract research organization, bioanalysis at a second laboratory, peer-reviewed histopathology at a third. The PI acts on behalf of the Study Director for defined delegated phases at a test site. The Study Director still approves the study plan and its amendments, approves the final report, and remains responsible for whether the study as a whole followed GLP. You cannot assign overall control to a PI.

Test facility management designates a PI when needed, documents replacement of a Study Director or PI, maintains a master schedule and a historical SOP file, names an archive individual, and keeps communication lines open among the Study Director, PI(s), quality assurance, and study personnel. The lead quality-assurance program verifies the study plan and inspects the assembled final report, including PI contributions and test-site quality-assurance statements.

Quality Assurance Unit independence

21 CFR 58.35 requires a Quality Assurance Unit (QAU) that monitors each study to assure management that facilities, equipment, personnel, methods, practices, records, and controls conform to Part 58. The critical sentence: for any given study, the QAU shall be entirely separate from and independent of the personnel engaged in the direction and conduct of that study.

A Study Director cannot quality-assure the study they direct. QAU staff inspecting Study X cannot sit in the Study Director’s reporting chain for Study X. In a small facility the same person might conduct Study A and inspect Study B, but never both roles on one protocol. 21 CFR 58.3(l) defines the QAU as any person or organizational element, except the study director , designated by testing facility management.

Independence is not a gag order. QAU immediately brings problems likely to affect integrity to the Study Director and management, and periodically submits written status reports to both. QAU also maintains the master schedule indexed by test article, keeps copies of protocols, inspects each study at intervals adequate to assure integrity, determines that protocol and SOP deviations were authorized and documented, reviews the final report to confirm it reflects the raw data, and signs a quality-assurance statement listing inspection dates and when findings were reported.

Management, amendments, deviations, raw data, and archives

21 CFR 58.31 requires testing facility management, for each study, to designate the Study Director before initiation, replace that person promptly if needed, assure a QAU exists, assure test and control articles have been appropriately tested for identity, strength, purity, and stability, and assure that personnel, resources, facilities, equipment, materials, and methodologies are available. Management authorizes significant changes to SOPs (21 CFR 58.81). Management does not co-sign away Study Director control of the protocol.

Amendments are planned protocol changes: documented, signed and dated by the Study Director, with reasons, and kept with the protocol before or as the change takes effect (for example, adding a recovery cohort after a documented design review). A deviation is an unplanned departure from the already-approved protocol or from SOPs — a missed blood collection, a temperature excursion, a diet mix-up. Deviations live in the raw data, are authorized by the Study Director, and are assessed for impact. QAU’s job is to confirm authorization and documentation, not to discover the event only while auditing the draft report.

Raw data (21 CFR 58.3) means laboratory worksheets, records, memoranda, notes, or exact copies that result from original observations and activities and are necessary to reconstruct and evaluate the report. Photographs, computer printouts, magnetic media, and verified transcripts of instrument files can be raw data. Corrections use a single-line strikethrough, initials, date, and reason — never an opaque overwrite.

21 CFR 58.190 requires orderly storage and retrieval of raw data, documentation, protocols, final reports, and specified specimens. An archivist (OECD language; FDA requires a designated individual) indexes the material and controls access. 21 CFR 58.195 sets retention from the disposition of the permit application the study supported, or, if results were never submitted, at least two years after the study is completed, terminated, or discontinued. Studies of more than four weeks also require reserve samples from each test and control article batch (21 CFR 58.105(d)).

Separate four inspection ideas on exam day: QAU critical-phase (study-based) inspections of live events such as first dose or necropsy; QAU facility or process inspections of shared systems (archive, computerized systems, animal care); QAU protocol and report audits ; and regulatory inspections of the testing facility (21 CFR 58.15, EPA inspectors, or OECD monitoring authorities). Under 21 CFR 58.35(d), FDA can require the dates of QAU inspections, the study and phase inspected, and the inspector’s name. Narrative QAU findings remain internal management tools; they do not replace the Study Director’s signed report.

Loading diagram... GLP roles: Test Facility Management, Study Director, QAU, Principal Investigator, and archivist